Note 12 - Related Party Transactions

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block]

(

12

)    Related Party Transactions

In

August 2016,

the Company granted an option to purchase

46,553

shares of common stock, with a

4

-year vesting period and an exercise price of

$16.20

per share, to OPKO Health, Inc. (“OPKO”) as consideration for consulting services to be provided by OPKO. BioCardia recorded approximately

$22,000

and

$44,000

as share-based compensation expense related to the OPKO stock option in selling, general and administrative expense during the

three

and

six

months ended

June 30, 2019,

respectively. BioCardia recorded approximately

$37,000

and

$62,000

as share-based compensation expense related to the OPKO stock option in selling, general and administrative expense during the

three

and

six

months ended

June 30, 2018,

respectively. The estimated grant-date fair value of the option was

$5.3

million. The term of the consulting agreement is

4

years and will be automatically renewed for successive

one

-year periods. The chairman and chief executive officer of OPKO is a beneficial owner of more than

5%

of the outstanding shares of the Company’s common stock.